89 studies found for:    "spinocerebellar degenerations" OR "marinesco-sjogren syndrome"
Show Display Options
RSS Create an RSS feed from your search for:
"spinocerebellar degenerations" OR "marinesco-sjogren syndrome"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
Conditions: Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 6
Intervention: Genetic: All Participants
2 Unknown  Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
Conditions: Spinocerebellar Ataxias;   Spastic Paraplegias
Intervention:
3 Completed
Has Results
Dalfampridine and Gait in Spinocerebellar Ataxias
Conditions: Spinocerebellar Ataxias Type 1;   Spinocerebellar Ataxias Type 2;   Spinocerebellar Ataxias Type 3;   Spinocerebellar Ataxias Type 6
Interventions: Drug: Dalfampridine;   Drug: Placebo
4 Recruiting A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
5 Recruiting An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
6 Recruiting A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose;   Drug: Placebo
7 Recruiting A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
8 Completed A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373;   Drug: Placebo
9 Completed Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Intervention: Drug: KPS-0373
10 Recruiting Transcranial Magnetic Stimulation in Spino-Cerebellar Ataxia
Condition: Spinocerebellar Ataxia
Intervention: Device: Transcranial Magnetic Stimulation
11 Completed Lithium Treatment for Patients With Spinocerebellar Ataxia Type I
Condition: Spinocerebellar Ataxia Type I
Intervention: Drug: Lithium Carbonate
12 Completed Measuring Neurological Impairment and Functional Visual Assessment In Spinocerebellar Ataxias
Condition: Spinocerebellar Ataxia
Intervention:
13 Completed Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
Conditions: Spinocerebellar Ataxia Type 3;   Machado Joseph Disease
Interventions: Drug: Lithium Carbonate;   Drug: Placebo
14 Completed Parkinsonism in Spinocerebellar Ataxia Type 6
Condition: Spinocerebellar Ataxia Type 6
Intervention:
15 Not yet recruiting Functional and Structural Imaging and Motor Control in Spinocerebellar Ataxia
Condition: Spinocerebellar Ataxia
Interventions: Behavioral: Error-reduction;   Behavioral: International Cooperative Ataxia Rating Scale;   Behavioral: Scale for the Assessment and Rating of Ataxia
16 Completed Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia
Condition: Spinocerebellar Ataxia
Intervention: Biological: IVIG
17 Recruiting An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias
Condition: Spinocerebellar Ataxias
Intervention: Drug: Intravenous Immune Globulin (IVIG)
18 Completed Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)
Condition: SPINOCEREBELLAR ATAXIA 2
Intervention: Drug: LITHIUM CARBONATE
19 Completed Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
Condition: Spinocerebellar Ataxia Type 3
Interventions: Drug: varenicline;   Drug: placebo
20 Active, not recruiting Biomarkers in Autosomal Dominant Cerebellar Ataxia
Conditions: Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia, Autosomal Recessive 3;   Episodic Ataxia, Type 7
Intervention: Other: metabolic and imaging biomarkers in SCA1,2,3 and 7 patients

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years